BridgeMD
Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms
EU CTIS ID: 2025-524344-35-00
What this study is testing
To assess at day 5 the effectiveness of acetazolamide added to conventional treatment on decongestion (interventional group) compared to standard treatment (control group) in patients with ambulatory HF previously treated with furosemide (with fraction of left ventricular ejection impaired or not) and monitored by remote monitoring
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥ 18
- Known HF with impaired, midly-reduced or preserved LVEF
- Under guideline directed medical therapy for HF according to ESC Heart Failure Guidelines applicable at inclusion
- Previously followed (or included at hospital discharge) by remote monitoring allowing daily weight by connected scale (i.e. Careline®, Optified-self®, NewCard®, Implicity®)
- Under furosemide diuretic treatment ≥ 20mg/day for at least 30 days prior to inclusion
- Current unplanned hospitalization or unplanned/emergent consultation for acute/decompensation HF
You likely can't join if
- Subject unable to express their consent and sign informed consent form
- Low cardiac output syndrome/cardiogenic shock
- Current use of acetazolamide or any other carbonic anhydrase inhibitor, including but not limited to topical ophthalmic formulations (e.g., brinzolamide, dorzolamide, methazolamide)
- Subject not covered by public health insurance
- Refusal to participate (absence of informed consent)
- Subject under guardianship, legal protection, or deprived of liberty
See the full eligibility criteria
- Age ≥ 18
- Known HF with impaired, midly-reduced or preserved LVEF
- Under guideline directed medical therapy for HF according to ESC Heart Failure Guidelines applicable at inclusion
- Previously followed (or included at hospital discharge) by remote monitoring allowing daily weight by connected scale (i.e. Careline®, Optified-self®, NewCard®, Implicity®)
- Under furosemide diuretic treatment ≥ 20mg/day for at least 30 days prior to inclusion
- Current unplanned hospitalization or unplanned/emergent consultation for acute/decompensation HF
- Subject unable to express their consent and sign informed consent form
- Low cardiac output syndrome/cardiogenic shock
- Current use of acetazolamide or any other carbonic anhydrase inhibitor, including but not limited to topical ophthalmic formulations (e.g., brinzolamide, dorzolamide, methazolamide)
- Subject not covered by public health insurance
- Refusal to participate (absence of informed consent)
- Subject under guardianship, legal protection, or deprived of liberty
- Pregnant or breastfeeding women
- Subject under law protection and prisoners
- Women of child bearing potential, unless they are using an effective method of birth control (i.e. oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner)
- Subject unable to comprehend or adhere to the protocol and follow-up
- Concurrent participation in another interventional study
- Chronic ventricular assist device or heart transplant patients
- Concomitant use of lithium, valproic acid and valpromide
- Current use of high-dose aspirin (>300 mg/day)
- Acute heart failure from recent acute coronary syndrome (< 1 month)
- Severe chronic renal failure or dialysis (GFR < 20 ml/min)
- History of renal colic, hyperchloremic acidosis and wheat allergy (other than coeliac disease)
- Known severe hepatic insufficiency defined by a PTT < 50% or a Child-Pugh score C and/or a known (clinial or biological) supplemented adrenal insufficiency
- Intolerance to sulphonamides
- Hypersensitivity to the active substance (Acetazolamide) or to any of the excipients (Calcium carbonate, wheat starch, gelatine, magnesium stearate)
- Concomitant use of carbamazepine or quinidinics (hydroquinidine, quinidine)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.